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The approach to treating vestibular schwannomas ranges
from wait-and-scan policies to micro-and radiosurgery.
However, in the past few decades, Stereotactic
Radiosurgery (SRS) has emerged as an approved primary
treatment option as well. In this review, we have assessed
some of the existing literature on the role of SRS in the
management of vestibular schwannomas, and to estimate
its efficacy in tumour control and conservation of cranial
nerve function.
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Introduction
Vestibular Schwannomas (VS) are primary brain tumours,
comprising 80% of the cerebellopontine lesions of the
brain.1 Throughout the last three decades, the
management strategies of VS have ranged from
observation to microsurgical resection and radiosurgery,
based on the Koos classification that stratify tumours
based on tumour volume, extra-meatal extension and
compression of the brainstem.1,2 Stereotactic radiosurgery
(SRS) has established itself as a valid treatment option for
solitary small/medium sized lesions, ranging from 25-30
mm in cisternal diameter, and for residual lesions after
microsurgical debulking.3-5
While microsurgical resection has remained the mainstay
of treatment for tumours more than 30mm and/or those
compressing the brainstem (Koos grade IV), SRS has
emerged as a popular treatment modality since Leksell
first used the Gamma Knife SRS (GK-SRS) to treat a VS in
1969. (4-6) The literature prior to 1992 reported increased
morbidity with SRS, majorly due to the lesion being treated
with higher tumour margin doses (16 Gy), or pseudo
progression of large VS following SRS.5,6 However, recent
studies reported improved outcomes with optimal dosing
(12-13 Gy), along with using sophisticated dose-planning
software and high-resolution stereotactic MRI.3,6 In this
study, we have reviewed the literature for long term patient
outcomes in patients undergoing SRS as the primary
treatment modality for small, medium and large sized
Vestibular Schwannomas. The studies are reported in
chronological order, the older papers reported first.
Review of Evidence
Kondziolka et al., in their 1998 landmark publication
reviewed 182 patients who had undergone GK-SRS at a
mean dose of 16.6 Gy as the primary treatment for VS.7 At
1 year of follow-up, 73.8% of the tumours had unchanged
volume, while 25.5% decreased in size. At 5 years, 72%
tumours had shrunk, with the lesion stable in the rest
28%. Preservation of pre-treatment facial nerve function
was seen in 79% while hearing was preserved in 51% of
the patients.7 In another landmark paper with 927 patients
studied prospectively, Regis et al., strongly supported the
use of GK-SRS for VS over microsurgery, in terms of tumour
control and preservation of functional hearing.8 The patient
population had lesions ranging from Koos grade I to grade
IV, with an average tumour volume of 12.7 mm3, and
useful hearing in at least 47% of the patients. Post-
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Figure-1:  MRI brain T1 with contrast showing a large heterogeneously
enhancing VS in right cerebellopontine angle, causing significant
compression of brainstem and obliteration of fourth ventricle.
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treatment tumour control at the last follow-up was 97%,
with hearing preservation in 62.7% of the patients at 3
years. Despite 42 stage 4 lesions included in the study,
only few permanent complications such as trigeminal
injury and facial palsy were noted in 0.6% and 1.3% of the
patient population, respectively.8
Nagano et al., prospectively analyzed 87 patients studying
the efficacy of GK-SRS.9 Mean tumour volume at the time
of presentation was 2.5 cm3 (ranging from 0.1 to 13.3 cm3,
with transient volume expansion in 58% of the tumours
at 8.6 months of follow-up. A 31% mean reduction in
tumour size was noticed at 5 years of follow-up, while 9
tumours progressed in size from their initial volumes.
Homogenously enhancing tumours were reported to
demonstrate less shrinkage. (9) Van De Langenberg et al.,
retrospectively reviewed 33 patients with large,
progressive, Koos grade IV VS which were more than 6
cm3 in size and at least indenting the brainstem.10 Mean
tumour volume at presentation was 8.8 cm3 (6.1-17.7 cm3)
and control was assessed at a median follow-up of 30
months. Radiological growth control and clinical growth
control were achieved in 88% and 76% of the patients,
respectively. Mild, transient complications of facial and
trigeminal neuropathy were noticed in 8 patients.
Preserved serviceable hearing, facial and trigeminal
functions were 58%, 91% and 86% respectively.10
Hayashi et al., in his study of 260 VS patients with tumours
ranging from Koos grade I through IV (0.1-9.0 cm3 tumour
volume), reported 94.6% loss of central contrast
enhancement at 6 months of follow-up and significant
transient enlargement of more than 2 mm in any
dimension in 25.8% of tumours at 12 months. At 3 years
of follow up with 182 patients, tumour control and
shrinkage were noted to be 98.4% and 76.4% respectively,
with more than 50% mean reduction in the tumour
volume. Pretreatment facial nerve function was preserved
in 97.8%, with improvement in 2.2% of the patient
population. Serviceable hearing was preserved in 87.9%
patients, with improved hearing in 7 patients (3.8%).4
After having reviewed 379 VS patients undergoing SRS
as primary treatment in 2014, Boari et al., concluded that
better outcomes could be achieved if the time between
symptom onset, diagnosis and treatment was shortened.11
Mean tumour volume at presentation was 1.94 cm3 (0.013
- 14.3 cm3), which was treated at a mean marginal dose
of 13Gy. Tumour control was achieved in 97.1%. 82.5%
tumours shrunk by a relative reduction of 34.1%.
Complication rate was low, with transient symptom
worsening being the most common complication.
Pretreatment symptoms of vertigo, balance disturbances,
and facial and trigeminal neuropathy were completely
resolved after treatment. However, there was no significant
resolution of tinnitus. A total of 49% of the patients had
preservation of functional hearing at long term follow-
up, with better hearing outcomes in younger patients.11
Iorio-Morin et al., evaluated 68 patients with Koos stage
IV VS undergoing primary treatment with GK-SRS.12
Median tumour volume at the time of presentation was
7.4 cm3 (4-19 cm3), with a baseline serviceable hearing in
60% of the patients. A median marginal dose of 12 Gy
was used. Actuarial tumour control was 92% at 10 years
of follow up. Hearing was preserved in 89% of the patients
at 2 years of follow up and decreased to 49% at 5 years.
Facial nerve function was preserved in 100% of the
patients. Balance disturbances, facial pain, facial numbness
and tinnitus were few of the reported complications,
however, all were mild and transient.12 Another study by
Bailo et al., evaluated 59 patients with VS greater than 2.5
cm3 in size, and concluded that while surgical resection
should remain the primary approach for large size VS, SRS
provided with a safe and effective alternative in patients
who were not good candidates for surgery. Mean tumour
volume at presentation was 5.98 cc, with maximum
Figure-2: Post-operative MRI brain T1 with contrast of the same patient
showing a small residual tumour.
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volume up to 14.3 cc. Tumour control and shrinkage were
achieved in 98.4% and 86.4% of the patients respectively.
Functional hearing was preserved in 31.3% of the patients.
However, 5.1% (n=3) patients developed a permanent
facial nerve deficit while 6.8% (n=4) people developed
new or worsened trigeminal impairment. New onset
hydrocephalus requiring treatment with VP shunt was
seen in 18.5% (n=10) of the patients.3
Lefranc et al., reviewed 86 patients with grade IV VS who
underwent primary treatment with GK-SRS and reported
GK-SRS to be safe and effective in patients with no
symptoms of brainstem compression or trigeminal
dysfunction at presentation. Patients were followed up
for 3-16 years and tumour control with no clinical
deterioration was achieved in 90.7% (n=78) of the patients.
36 patients had functional hearing loss before treatment,
which was preserved in 25 patients post treatment. 9.3%
of the cases underwent delayed surgical resection or
ventricular shunting for tumour growth after radiosurgery.5
Johnson et al., recently reported outcomes of 871 patients
who underwent treatment for VS primarily with GK-SRS.1
Median tumour volume was 0.9 cc (0.02-36 cc), and the
tumours were treated with a median marginal dose of 13
Gy. The follow-up period ranged from 1-25 years.
Progression Free Survival (PFS) was 97% at 3 years, 95%
at 5 years and 94% at 10 years follow up, with only 1.3%
of the patients undergoing subsequent microsurgical
resection for progressive tumour growth. Small tumour
volumes were reported to be associated with better PFS.1
326 patients had serviceable hearing (GR 1 or 2) at the
time of SRS, which was preserved in 89.8% at 1 year, 68.4%
at 5 years and 51.4% at 10 years of onset. Post-SRS 5.8%
(n=51) patients developed trigeminal neuropathy, while
1.6% of the patients developed a transient facial palsy of
House Brackman grade 2 to 3.1
Conclusion
SRS is an efficient treatment modality for small, medium,
and asymptomatic large sized vestibular schwannomas,
both in terms of tumour control, and cranial nerve
preservation. However, these studies do not report the
technical difficulties and morbidity associated with
microsurgical resection of post-SRS tumours, in cases
where SRS fails.
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